

# SVEN GEISSLER

Group Leader Musculoskeletal System | Nominee Non-Voting Member



## Scientific Development/ CV:

|               |  |
|---------------|--|
| Since 01/2015 | Deputy Head; Research Area 'Musculoskeletal System'; BCRT    |
| Since 01/2015 | Group Leader 'Prognostic Markers & Targeted Therapies'; BCRT |
| Since 09/2012 | Head "Cell Biology"; Julius Wolff Institute                  |
| 2011          | PhD (Dr.-Ing.), TU Berlin                                    |
| 2007          | Master of Science „Bioprocess Engineering“                   |
| 2005          | Dipl.-Ing. "Biotechnology"                                   |

## Expertise:

- Development/ validation of *in vitro* or *ex vivo* assays to assess/identify novel therapeutic targets, biomarker, and underlying pathomechanisms
- Biomarker identification, development of companion diagnostic and their clinical validation
- Implementation of biomarker strategies in clinical studies for personalized medicine approaches
- Development and pre-clinical validation of cell-based therapies to enhance endogenous regeneration
- Ability to work in multi-disciplinary teams and proven track record of scientific publications in peer reviewed journals

## Relevant Projects/ Highlights:

(Co-) Principle investigator of different BMBF-, DFG-, EU- funded projects, e.g. BioBone, HIPGEN, DFG Research Unit 2165. Coordinating principle investigator of the BCRT crossfield „ImmunoReg“.

# SVEN GEISSLER

Group Leader Musculoskeletal System | Nominee Non-Voting Member



The BCRT's great strength is the unique ability to combine patient-based studies with rigorous basic scientific research. As a whole, we delivered internationally renowned examples how this translational research approach can advance medical practice.

In the coming years - along with the integration of the BCRT into the BIH and its integration into the Charité - it is of importance to maintain this strength and if possible expand it. Due to the cooperative and interdisciplinary character of translational research, it is essential to provide an environment in which people from different disciplines, such as biology, chemistry, physics, engineering and especially medicine, can work and act together.

In a world dominated by impact factors, patents and the acquisition of third party funding, we sometimes forget what the ultimate prerequisite for such an environment is – mutual trust, respect and appreciation of each other's performance and contribution. I'm convinced that scientific success is rarely an individuals' achievement, but always a joint effort of many.